Anderson Bethany, Snider Melissa J, Hansen Margaret, Parks Caitlin, Bagnola Aaron, Li Junan, Freimer Miriam, Segal Benjamin
J Am Pharm Assoc (2003). 2024 Mar-Apr;64(2):492-498.e1. doi: 10.1016/j.japh.2024.01.010. Epub 2024 Jan 19.
Patients with neurologic diseases have complex medical needs and may benefit from the addition of clinical pharmacists in their care.
This study aimed to describe integration and benefit of clinical pharmacists in neuroimmunology and neuromuscular clinics at an academic medical center.
This retrospective chart review evaluated patients initiated on a neurology medication for a neuroimmunology or neuromuscular disease state before and after pharmacist integration in neurology clinics. The primary outcome measured access to an initially prescribed neuroimmunology or neuromuscular medication within 90 days of prescription. Secondary outcomes included access to an initially prescribed or alternative neurology medication owing to insurance requirements within 90 days, time from initial prescription to start, and description of pharmacist involvement.
There were 101 patients in the pregroup and 101 patients in the postgroup. The percentage of patients with confirmed initially prescribed medication access at 90 days increased in the postgroup compared with the pregroup (87.1% vs. 72.5%, respectively, P = 0.014). For secondary outcomes, the percentage of patients who started on an initially prescribed or alternative neuroimmunology or neuromuscular medication within 90 days also increased in the postgroup compared with the pregroup (90.0% vs. 73.3%, respectively, P = 0.004). Additional pharmacist involvement occurred in 64 patients (63.4%) in the postgroup and included prior authorization approval assistance, drug information support, and medication liaison interventions, with an average of 4.7 pharmacist interventions at each pharmacy-led encounter.
The addition of pharmacists into neuroimmunology and neuromuscular clinics improved operational access to medications for neuroimmunology and neuromuscular conditions. In addition, pharmacists were able to assist with multiple areas of patient care including medication education, monitoring, and serving as a medication liaison. This study supports continuing to offer clinical pharmacy services in neuroimmunology and neuromuscular departments and may support the addition of clinical pharmacists into neurology services at other institutions.
神经系统疾病患者有复杂的医疗需求,在其治疗中增加临床药师可能会受益。
本研究旨在描述临床药师在一家学术医疗中心的神经免疫学和神经肌肉诊所中的整合情况及带来的益处。
这项回顾性病历审查评估了在神经内科诊所药师整合前后因神经免疫学或神经肌肉疾病状态开始使用神经科药物治疗的患者。主要结局指标为在处方开具后90天内获得最初处方的神经免疫学或神经肌肉药物的情况。次要结局指标包括因保险要求在90天内获得最初处方或替代神经科药物的情况、从最初处方到开始用药的时间,以及药师参与情况的描述。
分组前有101例患者,分组后有101例患者。与分组前相比,分组后90天内确认获得最初处方药物的患者百分比有所增加(分别为87.1%和72.5%,P = 0.014)。对于次要结局指标,与分组前相比,分组后在90天内开始使用最初处方或替代神经免疫学或神经肌肉药物的患者百分比也有所增加(分别为90.0%和73.3%,P = 0.004)。分组后有64例患者(63.4%)得到了药师的额外参与,包括事先批准协助、药物信息支持和药物联络干预,在每次由药房主导的会诊中平均有4.7次药师干预。
在神经免疫学和神经肌肉诊所增加药师改善了神经免疫学和神经肌肉疾病用药的可及性。此外,药师能够在患者护理的多个领域提供帮助,包括药物教育、监测以及担任药物联络人。本研究支持继续在神经免疫学和神经肌肉科室提供临床药学服务,并可能支持在其他机构的神经内科服务中增加临床药师。